Defunct Company
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
7
NCT05348889
First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies
Phase: Phase 1/2
Role: Lead Sponsor
Start: Aug 30, 2022
Completion: Oct 31, 2024